KalVista Pharmaceuticals is a global biopharmaceutical company dedicated to developing and delivering life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. Our commitment to rigorous science is driven by our determination to better address treatment needs for patients, beginning with our first product for hereditary angioedema (HAE), a rare genetic disease with unpredictable attacks of tissue swelling that can be life threatening.
Our debut rare disease therapy was approved by the FDA as the first and only oral on-demand treatment for HAE and has the potential to transform HAE treatment worldwide. As an oral medication, it is designed to offer an alternative to the complexities and treatment burden of other approved HAE treatment options, which require injectable administration or chronic dosing.
Our pipeline innovations include preclinical programs for oral Factor XIIa inhibitors, expanding our HAE product portfolio to include prophylactic treatment of HAE, as well as pushing ahead with new treatments for other diseases, such as thrombosis and inflammation.
